Technologies

This invention describes specific radiopharmaceuticals and a method for using positron emission

tomography (PET) to accurately predict autosomal dominant polycystic kidney disease (ADPKD)

progression in the early stages of disease. ADPKD is the fourth leading cause of kidney failure in the

U.S. In spite of significant structural damage, renal function in ADPKD patients is maintained within

a normal range until the late stage of the disease. Thus, the effectiveness of a therapeutic intervention

is low in ADPKD patients with established renal insufficiency since significant structural damage has

already occurred. However, no diagnostic tool is currently available to identify patients who are at

higher risk of rapidly progressing ADPKD and would be more likely to benefit from a therapeutic

intervention. The invention disclosed here will fulfill this clinical need.